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SUMMARY: Pregnancy related changes in oxidative metabolism of model 
substrates were examined in CD1 mice. As compared to nonpregnant females, a 
significant decrease in the hepatic microsomal aminopyrine-but not in 
dimethylaniline-N-demethylase activity was observed in pregnant mice. The 
rates of microsomal flavin-containing monooxygenase-catalyzed N-oxidation of 
dimethylaniline remained relatively unchanged during pregnancy in the liver, 
lung, kidney, and uterus. In contrast to this, N-oxidase activity of 
placental microsomes was increased nearly 5-fold when measured at day 12 and 
18 of gestation. 
While most investigations on the oxidative metabolism of xenobiotics 
have concerned the microsomal heme-containing cytochrome P-450 system, 
several reports have also established the role of the MFMO in the N- and 
S-oxidation of xenobiotics including carcinogens, drugs, and pesticides (l-3). 
Using DMA as a model substrate, MFMO activity has been demonstrated in many 
animal species (4). Reports indicate that it is present in many tissues 
including adrenal, bladder mucosa, corpus luteum, liver, lung, kidney, thymus, 
ma thyroid (4). In contrast to the several reports (5-9) indicating a 
general depression of the microsomal cytochrome P-450-dependent monooxygenase 
system during pregnancy, there is only one report on the changes in MFMO 
activity during pregnancy (10). In this report, Devereux and Fouts (10) 
observed no change in the liver MFMO but detected a 57% increase in lung MFMO 
activity in 28 day pregnant rabbits. The purpose of our work was to examine 
MFMO activity in different tissues of mice during pregnancy. We are also 
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reporting for the first time significant amounts of MFMO activity in uterine 
and placental microsomes. In addition, data on the changes in the rates of 
hepatic microsomal N-demethylation of DM4 and AP during pregnancy in mice 
are presented. 
MATERIALS AND METHODS -~ 
Animals: 
used. 
CD1 mice purchased from Charles River Breeding Labs., Wilmington, MA were 
Mice were maintained on a 12 hour day/night cycle and had access to 
food and water ad libitum. -- Presence of a vaginal plug marked day 0 of 
gestation. 
Tissue Preparation: 
Immediately after sacrifice bv cervical dislocation, tissues were removed 
and homogenized in a medium containing ice-cold 0.25 M sucrose, 50 mM Tris, 
pH 7.4, and 0.1 mM EDTA. The homogenate was centrifuged at 9000 g for 20 
minutes and the supernatant decanted and centrifuged at 105,000 g for 60 
minutes. The microsomal pellet was suspended in 100 mM glycine, 25 mM 
phosphate buffer, pH 8.4. Protein estimation was by the biuret method (11). 
Enzyme Assays: 
MFMO activity of microsomes was determined by measuring the rate of DMA 
N-oxide formation according to the method described by Ziegler and Petit (12). 
DMA was purchased from Aldrich Chemical Co., Milwaukee, WI, and was 
redistilled prior to use. Incubation medium (total volume 1.0 ml) consisted 
of 100 mM glycine, 25 mM phosphate buffer, pH 8.4, 2.4 mM N-octylamine, 2.0 mg 
microsomal protein, and NADPH generating system consisting of 2.5 mM 
glucose-6-phosphate, 1.0 mM NADP, and 1 unit of glucose-6-phosphate 
dehydrogenase. Following preincubation at 37' with shaking for 3 min., 
reactions were started with the addition of DMA (1.0 mM). Incubations were 
for 10 min. with shaking at 37". 
DMA- and AP-demethylase activities were estimated in the absence of 
n-octylamine using incubation media (1.0 ml total volume) containing 100 mM 
Tris buffer pH 7.4, 1.0 mg microsomal protein, NADPH generating system as 
described above, and either 1.0 mM DMA or 5.0 mM AP. Following incubation 
for 10 min. (DMA) or 30 min. (AP) at 37', reactions were terminated with 
1.5 ml ice-cold 12.5% TCA. The amount of formaldehyde produced was measured 
by the Nash method (13). The non-enzymatic controls consisted of standard 
incubations with the appropriate buffer in place of microsomal suspensions. 
Statistical analysis was by one way analysis of variance and Bonferonni 
comparison of group means (14). 
RESULTS AND DISCUSSION 
Table 1 shows MFMO activity in various extrahepatic tissues of pregnant 
and nonpregnant mice. Pregnancy had no statistically significant effect on 
MFMO in either the lung, kidney, or uterus, although some decline in activity 
was observed in the latter two tissues. The fact that we aid not find an 
increase in MFMO activity in lung microsomes from pregnant mice as reported 
for rabbits (10) suggests a species difference in either the MFMO enzyme 
molecule itself and/or in the endogenous modifying factors affecting lung 
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Table 1. Changes in MFMO activity of the mouse extrahepatic tissues during 
pregnancy. Assays were carried out as described under Materials and Methods. 
MFMO activity is expressed as nmoles of DMA N-oxide formed/min/mg microsomal 
protein. Values represent mean + S.E. (n). Relative MPMO activities are 
given in parentheses below means. 
Tissue MPMO Activity 
Non-pregnant Pregnant 
Day 12 Day 18 
Uterus 0.59 + 0.13 (5) 0.26 + 0.04 (5) 0.43 + 0.18 (5) 
(100) (44) (73) 
Kidney 1.44 + 0.08 (5) 0.77 f. 0.18 (5) 1.26 + 0.26 (5) 
(100) (53) (88) 
Lung 1.00 + 0.03 (4) 1.15 f  0.11 (4) 0.96 + 0.02 (4) 
(100) (115) (96) 
Placenta -- 0.29 + 0.03 (8) 1.40 f  0.02*(7) 
(100) (483) 
*Significantly different, P 5 0.05 
MFMO activity during pregnancy. In addition to these tissues, we have 
detected significant N-oxidase activity in the mouse placenta. The activity 
was low at day 12 of gestation, but increased nearly five-fold reaching a 
level that was about 50% of maternal liver IQMO (Table 2) by day 18 of 
gestation. 
In vitro studies of placental xenobiotic oxidation are complicated by -- 
the hemoglobin contamination of microsomes. Available information, however, 
suggests that hemoglobin-mediated oxidation is not a general phenomenon 
applicable to all the xenobiotics undergoing oxidation: but is rather 
substrate specific (15). Furthermore, due to poor affinity, very high sub- 
strate concentrations are required to observe low measurable activity. Thus, 
in contrast to 1.0 mM DMA employed in this study, Blisard and Mieyal (16) 
reported a need to use 40 mM aniline to measure p-hydroxylase activity of 
hemoglobin. We have determined that in standard tissue-free DMA incubations 
hemoglobin could catalyze the formation of 0.29 nmoles of DMA N-oxide/min/mg 
hemoglobin. Despite expected substantial variation in the degree of 
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Table 2. Changes in the mouse hepatic microsomal monooxygenase activities 
during pregnancy. Assays were carried out as described under Materials and 
Methods. HPMO activity is expressed as nmoles of DMA N-oxide formed/min/mg 
microsomal protein while N-demethylase activities are expressed as nmoles of 
formaldehyde produced/min/mg microsomal protein. Values represent mean + 
S.E. (n). Relative activities are given in parentheses below means. 
Status MFMO DMA N-demethylase AP N-demethylase 
Non-pregnant 2.77 + 0.15 (13) 1.79 + 0.11 (5) 6.81 5 0.28 (11) 
(100) (100) (100) 
Pregnant (Day 12) 3.14 + 0.08 (11) 1.70 4 0.08 (9) 5.73 + 0.32*(13) 
(113) (95) (84) 
Pregnant (Day 18) 2.66 f. 0.15 (12) 1.98 2 0.20 (5) 5.44 + 0.28* (9) 
(96) (111) (80) 
* Significantly different from non-pregnant, P 5 0.01. 
hemoglobin contamination, fairly uniform MPMO activities were found in the 
different preparations of placental microsomes (Table 1). In view of these 
points and the fact that MF'MO specific activity increased markedly toward 
the end of gestation strongly suggest that the observed placental DMA N-oxide 
formation is chiefly catalyzed by the constitutive microsomal MFMO and not by 
the contaminating hemoglobin. These observations are noteworthy since, to 
our knowledge, MFMO activity has not been reported in placental microsomes of 
any animal species before. More importantly, placental MF'MO activity near 
term appears to be quite high compared to the barely detectable levels 
reported for microsomal cytochrome P-450 dependent xenobiotic metabolizing 
activities (17). This suggests that MFMO represents a major oxidative 
pathway in the placenta during pregnancy and may perform an important role 
in xenobiotic metabolism in an otherwise oxidative deficient fetal-placental 
unit. These results are important since DMA-N-oxide has been shown to cause 
methemoglobinemia in mammals (18). Placental formation of DMA-N-oxide may 
have toxicologic implications to the fetus since fetal hemoglobin has been 
shown to be more readily oxidized to methemoglobin than is adult and the 
fetus is recognized to be deficient in NADH-methemoglobin reductase (19). 
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The data on the changes in the levels of hepatic microsond m0, DMA 
N-demethylase, and AP N-demethylase activities are given in Table 2. Although 
as compared to nonpregnant mice the mean MFMO activity appears to increase at 
day 12 of gestation, the difference is not statistically significant. 
Likewise, there was no change in DMA N-demethylase activity during pregnancy. 
This is in contrast to AP N-demethylase activity which was decreased 
significantly (20 per cent) in pregnant mice on day 12 and 18 of gestation 
as compared to nonpregnant mice. Earlier, Feuer and Kardish (9) as well as 
Dean and Stock (6) also observed a decrease in AP N-demethylation in pregnant 
rats. Although purportedly a cytochrome P-450-dependent reaction, it appears 
that the particular species of cytochrome P-450 responsible for the 
demethylation of DMA may not be affected by pregnancy. Alternatively, in 
mouse liver microsomes, formation of the N-oxide by MFMO prior to demethy- 
lation (12) may be the rate-limiting step for the release of formaldehyde to 
the extent that changes in the cytochrome P-450-dependent demethylase may not 
affect the overall demethylation of DMA, 
Turcan et al. (20) have shown a significant decrease in the proportion -- 
of cytochrome P-450 in the high spin state in microsomes from pregnant rats. 
The spin state of the cytochrome P-450 is important in overall metabolism 
since a shift to a lower spin state may alter the redox potential of the 
NADPH cytochrome P-450 reductase-hemoprotein coupling causing a reduction 
in electron flow to the hemoprotein and decreased metabolism of substrates 
Cm. In contrast to the cytochrome P-450, the MFMO may not be sensitive to 
those modulators that changes the spin state of the cytochrome P-450 
hemoprotein. 
There are several reports on the effect of pregnancy-induced changes in 
the hepatic microsomal phospholipid composition that leads to altered rates 
of cytochrome P-450-mediated xenobiotic metabolism (9, 22). The importance 
of phospholipids in cytochrome P-450-dependent oxidative reactions is well 
established (23, 24). In contrast, phospholipid is not an absolute require- 
ment for activity of MFMO (25). Hence pregnancy-related changes in phospholi- 
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pids could conceivably affect cytochrome P-450-related metabolism but not 
that mediated by MFMO. 
An elevation of serum levels of progestational hormones has been noted 
during pregnancy (22). Evidence that steroid hormones play an important 
role in regulating hepatic microsomal cytochrome P-450 dependent xenobiotic 
metabolism is also available. Inhibition of oxidative metabolism of AP, 
aniline, and hexobarbital (26, 27) as well as stimulation of biphenyl 
2-hydroxylation (28) is known. 
Our work suggests that, unlike the cytochrome P-450 system, MFMO may 
not be inhibited by high in vivo concentrations of progestational steroids. -- 
This is consistent with the report of Duffel et. al. (29) that progesterone -- 
treatment of gonadectomized female mice did not elevate microsomal DMA 
N-oxidase activity in either kidney, liver, or lung above that of 
gonadectomized controls. Exactly how high serum levels of the progestational 
hormones present during pregnancy relate to the effects we see in vitro is -- 
uncertain. Devereaux and Fouts (10) noted that microsomal progesterone 
levels did not differ between pregnant and non pregnant rabbits, however 
they did not measure levels of progesterone precursors or its metabolites. 
Indeed some of the progesterone metabolites have been shown to be more 
effective inhibitors of cytochrome P-450 catalyzed reactions than pro- 
gesterone itself (27). Whether the same is true in the mouse is presently 
unknown and further studies are necessary to clarify this point. 
Hepatic microsomes possess high affinity binding sites for steroid 
hormones (30, 31) and it is suggested that the observed binding does not 
reflect binding to steroid metabolizing enzymes; rather it represents an 
interaction with effector sites which may modulate microsomal metabolism 
(3) * Our preliminary observations that in vitro addition of either -- 
pregnenolone or pregesterone results in stimulation rather than inhibition 
of hepatic microsomal MFMO activity (unpublished results) are consistent 
with this view. 
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In conclusion, our data suggest that: 
a. The depression in cytochrome P-450-mediated metabolism of xenobiotics 
reported previously (5-9) is not a general phenomenon but is specific 
for certain substrates. 
b. MFMO activity of different tissues does not decline during pregnancy, 
hence overall in vivo oxidation of the compounds metabolized by both -- 
MFMO and cytochrome P-450 may not alter in pregnant animals. 
c. MFMO is present in the mouse placental microsomes and its titer increases 
toward term. Therefore, metabolism by MFMO may represent one of the 
important determinants of fetal exposure to environmental chemicals. 
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